Palatin Technologies Participates In Canaccord Genuity's 40th Annual Growth Conference

Rhea-AI Summary

Palatin Technologies, Inc. (NYSE American: PTN) participated in Canaccord Genuity's 40th Annual Growth Conference on August 13, 2020, engaging in a Fireside Chat hosted by John Newman. CEO Carl Spana and CFO Stephen T. Wills represented the company during the virtual event. The discussion focused on Palatin's specialized biopharmaceutical developments, particularly its first-in-class medicines targeting melanocortin and natriuretic peptide receptor systems. A webcast replay is available on the company's website for 90 days.

Positive

• Participation in a prestigious conference enhances visibility in the biopharmaceutical sector.
• Engagement with investors via webcast demonstrates transparency and commitment to stakeholder communication.

Negative

• The lack of new product announcements or clinical trial updates may lead to investor concerns over future growth.

CRANBURY, N.J., Aug. 13, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, announced that it participated in Canaccord Genuity's 40^th Annual Growth Conference in a Fireside Chat today at 10:30 am ET.  The conference was held virtually.

Carl Spana, Ph.D., President and Chief Executive Officer and Stephen T. Wills, Chief Financial Officer and Chief Operating Officer of Palatin Technologies, participated in the Fireside Chat hosted by John Newman of Canaccord Genuity.

The Fireside Chat was webcast.  The webcast replay can be accessed by logging on to the "Investor/Webcasts" section of Palatin's website at http://www.palatin.com or by clicking the following link:  https://wsw.com/webcast/canaccord42/ptn/.  The webcast will be available for 90 days.

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.Palatin.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/palatin-technologies-participates-in-canaccord-genuitys-40th-annual-growth-conference-301112185.html

SOURCE Palatin Technologies, Inc.

FAQ

What did Palatin Technologies discuss at the Canaccord Genuity's 40th Annual Growth Conference?

Palatin Technologies discussed their specialized biopharmaceutical developments and first-in-class medicines targeting melanocortin and natriuretic peptide receptor systems.

Who represented Palatin Technologies at the conference?

Carl Spana, CEO, and Stephen T. Wills, CFO, represented Palatin Technologies during the Fireside Chat.

When did Palatin Technologies participate in the Canaccord Genuity conference?

Palatin Technologies participated in the conference on August 13, 2020, at 10:30 am ET.

Where can I access the webcast of Palatin's Fireside Chat?

The webcast replay can be accessed on Palatin's website under the 'Investor/Webcasts' section.

What is the stock symbol for Palatin Technologies?

The stock symbol for Palatin Technologies is PTN.